Cargando…

Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment—A Review From the Melanoma Perspective and Beyond

BACKGROUND: Immune checkpoint inhibition (ICI) with anti-CTLA-4 and/or anti-PD-1 antibodies is standard treatment for metastatic melanoma. Anti-PD-1 (pembrolizumab, nivolumab) and anti-PD-L1 antibodies (atezolizumab, durvalumab, and avelumab) have been approved for treatment of several other advance...

Descripción completa

Detalles Bibliográficos
Autores principales:	Buder-Bakhaya, Kristina, Hassel, Jessica C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6031714/ https://www.ncbi.nlm.nih.gov/pubmed/30002656 http://dx.doi.org/10.3389/fimmu.2018.01474

Ejemplares similares

Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma
por: Hassel, Jessica C., et al.
Publicado: (2017)

Arthralgia Induced by BRAF Inhibitor Therapy in Melanoma Patients
por: Salzmann, Martin, et al.
Publicado: (2020)

Plasma glycoproteomic biomarkers identify metastatic melanoma patients with reduced clinical benefit from immune checkpoint inhibitor therapy
por: Pickering, Chad, et al.
Publicado: (2023)

Biomarkers for Immune Checkpoint Inhibitors in Melanoma
por: Kitano, Shigehisa, et al.
Publicado: (2018)

Sex Disparities of Genomic Determinants in Response to Immune Checkpoint Inhibitors in Melanoma
por: Shi, Fuyan, et al.
Publicado: (2021)

Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities
por: Xu, Ya, et al.
Publicado: (2020)

Landscape and Clinical Significance of Immune Checkpoint in Cutaneous Melanoma
por: Mao, Rui, et al.
Publicado: (2021)

An Immune-Related Gene Pair Index Predicts Clinical Response and Survival Outcome of Immune Checkpoint Inhibitors in Melanoma
por: Yan, Junya, et al.
Publicado: (2022)

Beyond First-Line Immune Checkpoint Inhibitor Therapy in Patients With Hepatocellular Carcinoma
por: Sharma, Rohini, et al.
Publicado: (2021)

Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma
por: Zhang, Wenjing, et al.
Publicado: (2022)

Biomarkers of the Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
por: Chen, Siteng, et al.
Publicado: (2020)

Fibroblast growth factor receptor family mutations as a predictive biomarker for immune checkpoint inhibitors and its correlation with tumor immune microenvironment in melanoma
por: Zhang, Wengang, et al.
Publicado: (2022)

Expanding the applications of immune checkpoint inhibitors in advanced lung cancer beyond disease progression
por: Chen, Chao, et al.
Publicado: (2023)

Rapid disease progression on immune checkpoint inhibitors in young patients with stage IV melanoma
por: Machiraju, Devayani, et al.
Publicado: (2023)

Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma
por: Khair, Duaa O., et al.
Publicado: (2019)

Immunosuppressive capacity of circulating MDSC predicts response to immune checkpoint inhibitors in melanoma patients
por: Petrova, Vera, et al.
Publicado: (2023)

Editorial: Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer
por: Dermime, Said, et al.
Publicado: (2021)

Research Progress of Biomarkers for Immune Checkpoint Inhibitors on Digestive System Cancers
por: Wang, Jingting, et al.
Publicado: (2022)

Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade
por: Peranzoni, Elisa, et al.
Publicado: (2020)

B Cells in Patients With Melanoma: Implications for Treatment With Checkpoint Inhibitor Antibodies
por: Willsmore, Zena N., et al.
Publicado: (2021)

Altered Frequencies and Functions of Innate Lymphoid Cells in Melanoma Patients Are Modulated by Immune Checkpoints Inhibitors
por: Cristiani, Costanza Maria, et al.
Publicado: (2022)

Utomilumab in Patients With Immune Checkpoint Inhibitor-Refractory Melanoma and Non-Small-Cell Lung Cancer
por: Hong, David S., et al.
Publicado: (2022)

Identification of fatty acid metabolism–related molecular subtype biomarkers and their correlation with immune checkpoints in cutaneous melanoma
por: Xu, Yujian, et al.
Publicado: (2022)

Soluble biomarkers to predict clinical outcomes in non-small cell lung cancer treated by immune checkpoints inhibitors
por: Ancel, Julien, et al.
Publicado: (2023)

Soluble immune checkpoints and T-cell subsets in blood as biomarkers for resistance to immunotherapy in melanoma patients
por: Machiraju, Devayani, et al.
Publicado: (2021)

Biomarkers of related driver genes predict anti-tumor efficacy of immune checkpoint inhibitors
por: Jiang, Shuai, et al.
Publicado: (2022)

Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: Work still in progress
por: Perrino, Matteo, et al.
Publicado: (2023)

CAXII inhibitors: Potential sensitizers for immune checkpoint inhibitors in HCC treatment
por: Han, Rui, et al.
Publicado: (2023)

Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma
por: Patterson, Andrew, et al.
Publicado: (2022)

Case Report: Simultaneous Hyperprogression and Fulminant Myocarditis in a Patient With Advanced Melanoma Following Treatment With Immune Checkpoint Inhibitor Therapy
por: Barham, Whitney, et al.
Publicado: (2021)

Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond
por: Lee, Yun Hua, et al.
Publicado: (2020)

Evaluating distinct KRAS subtypes as potential biomarkers for immune checkpoint inhibitor efficacy in lung adenocarcinoma
por: Wang, Qi, et al.
Publicado: (2023)

Features of patients with advanced EGFR-mutated non-small cell lung cancer benefiting from immune checkpoint inhibitors
por: Chen, Qian, et al.
Publicado: (2022)

Checkpoint blocker induced autoimmunity as an indicator for tumour efficacy in melanoma
por: Hassel, Jessica C.
Publicado: (2021)

Mechanisms of Immune Checkpoint Inhibitor-Mediated Colitis
por: Westdorp, Harm, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors in Human Glioma Microenvironment
por: Ghouzlani, Amina, et al.
Publicado: (2021)

Advances in immune checkpoint inhibitors induced-cardiotoxicity
por: Li, Xiang, et al.
Publicado: (2023)

Cutaneous manifestations associated with immune checkpoint inhibitors
por: Watanabe, Tomoya, et al.
Publicado: (2023)

Biomarkers for Outcome in Metastatic Melanoma in First Line Treatment with Immune Checkpoint Inhibitors
por: Mesti, Tanja, et al.
Publicado: (2023)

Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma
por: Lelliott, Emily J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3142bq0ts4ra8ccaf4j1poqimj